A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC)
Rami Nassabein,
Pierre-Olivier Gaudreau,
Wiam Belkaid,
Marie Florescu,
Normand Blais
Affiliations
Rami Nassabein
Hematology and Medical Oncology Service, Department of Medicine, Centre Hospitalier Universitaire de Montréal, Université de Montréal, Montréal, H2 X 3E4, Canada
Pierre-Olivier Gaudreau
Department of Oncology, Queen's University, Kingston, Ontario, Canada
Wiam Belkaid
Hematology and Oncology, Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 St-Denis St, Montreal, QC, H2 X 0A9, Canada
Marie Florescu
Hematology and Medical Oncology Service, Department of Medicine, Centre Hospitalier Universitaire de Montréal, Université de Montréal, Montréal, H2 X 3E4, Canada
Normand Blais
Hematology and Medical Oncology Service, Department of Medicine, Centre Hospitalier Universitaire de Montréal, Université de Montréal, Montréal, H2 X 3E4, Canada; Hematology and Oncology, Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 St-Denis St, Montreal, QC, H2 X 0A9, Canada; Corresponding author at: Center Hospitalier de l'Université de Montréal, 1000 Rue Saint Denis, Montréal, QC, H2 X 0C1, Canada.
